

# Peroxisome proliferator-activated receptor $\alpha$ mediates enhancement of gene expression of cerebroside sulfotransferase in several murine organs

Takero Nakajima · Yuji Kamijo · Huang Yuzhe ·  
Takefumi Kimura · Naoki Tanaka · Eiko Sugiyama ·  
Kozo Nakamura · Mamoru Kyogashima ·  
Atsushi Hara · Toshifumi Aoyama

Received: 23 August 2012 / Revised: 26 September 2012 / Accepted: 1 October 2012 / Published online: 13 October 2012  
© Springer Science+Business Media New York 2012

**Abstract** Sulfatides, 3-*O*-sulfogalactosylceramides, are known to have multifunctional properties. These molecules are distributed in various tissues of mammals, where they are synthesized from galactosylceramides by sulfation at C3 of the galactosyl residue. Although this reaction is specifically catalyzed by cerebroside sulfotransferase (CST), the mechanisms underlying the transcriptional regulation of this enzyme are not understood. With respect to this issue, we previously found potential sequences of peroxisome proliferator-activated receptor (PPAR) response element on upstream regions of the mouse CST gene and presumed the possible regulation by the nuclear receptor PPAR $\alpha$ . To confirm this hypothesis, we treated wild-type and *Ppara*-null mice with the specific PPAR $\alpha$  agonist fenofibrate and examined the amounts of sulfatides and CST gene

expression in various tissues. Fenofibrate treatment increased sulfatides and CST mRNA levels in the kidney, heart, liver, and small intestine in a PPAR $\alpha$ -dependent manner. However, these effects of fenofibrate were absent in the brain or colon. Fenofibrate treatment did not affect the mRNA level of arylsulfatase A, which is the key enzyme for catalyzing desulfation of sulfatides, in any of these six tissues. Analyses of the DNA-binding activity and conventional gene expression targets of PPAR $\alpha$  has demonstrated that fenofibrate treatment activated PPAR $\alpha$  in the kidney, heart, liver, and small intestine but did not affect the brain or colon. These findings suggest that PPAR $\alpha$  activation induces CST gene expression and enhances sulfatide synthesis in mice, which suggests that PPAR $\alpha$  is a possible transcriptional regulator for the mouse CST gene.

T. Nakajima · Y. Kamijo (✉) · H. Yuzhe · T. Kimura · N. Tanaka ·  
E. Sugiyama · A. Hara · T. Aoyama  
Department of Metabolic Regulation,  
Institute of Pathogenesis and Disease Prevention,  
Shinshu University Graduate School of Medicine,  
3-1-1 Asahi,  
Matsumoto, Nagano 390-8621, Japan  
e-mail: yujibeat@shinshu-u.ac.jp

Y. Kamijo  
Department of Nephrology,  
Shinshu University School of Medicine,  
Matsumoto, Nagano, Japan

H. Yuzhe  
Department of Human Anatomy, Hebei Medical University,  
Shijiazhuang, Hebei, China

T. Kimura  
Department of Gastroenterology,  
Shinshu University School of Medicine,  
Matsumoto, Nagano, Japan

E. Sugiyama  
Department of Nutritional Science,  
Nagano Prefectural College,  
Nagano, Nagano, Japan

K. Nakamura  
Department of Bioscience and Biotechnology,  
Faculty of Agriculture, Shinshu University,  
Minami-Minowa, Kami-Ina, Nagano, Japan

M. Kyogashima  
Division of Microbiology and Molecular Cell Biology,  
Nihon Pharmaceutical University,  
Ina, Kita-Adachi, Saitama, Japan

**Keywords** CST · Fenofibrate · PPAR $\alpha$  · Sphingoglycolipid · Sulfoglycolipid

## Introduction

Sulfatides are sulfoglycolipids composed of ceramides, galactoses, and sulfates. Sulfatides are widely expressed in mammalian tissues, such as brain, kidney, liver, and digestive tract, mainly at the outer leaflet of the biological membrane [1]. Several studies have proposed the biological functions of sulfatides in various fields, including the nervous system, immune system, glucose metabolism, osmotic regulation, spermatogenesis, thrombosis/hemostasis, microbial infection, and cancer [1–3]. Therefore, sulfatide metabolism dysfunction might lead to the development of various diseases [2]. The multifunctional property of sulfatides is thought to be associated with the diversity of their chemical structures. Depending on the ceramide moiety, various molecular species of sulfatides exist, whose expression pattern and level are specific in tissues [1, 2]. Therefore, understanding the regulatory mechanism of sulfatide metabolism in various tissues may be important.

Sulfatides are synthesized from galactosylceramides by sulfation at C3 of the galactosyl residue. This reaction is catalyzed only by cerebroside sulfotransferase (CST) [3]. In contrast, sulfatides are degraded in this reverse reaction that is catalyzed by arylsulfatase A (ARSA) [1, 2]. However, there is little information about the transcriptional regulators for these key enzymes in sulfatide metabolism. We previously reported that CST gene expression was affected by oxidative stress and inflammation in mice [4, 5]. We have proposed several transcription factors involved in these phenomena by searching through the upstream regions of the mouse CST gene [4–7]. During this search, we also found putative sequences of peroxisome proliferator-activated receptor (PPAR) response element (PPRE): -1,434/-1,422 (AGGTCTAAGGGCA), -1,202/-1,190 (TGGACTTTGCCCT), and -896/-884 (AGGACAAAGAGCA) from exon 1a; -1,499/-1,487 (AGGCTACAGTTCA) from exon 1e; and -1,569/-1,557 (AGGTCAGAGCACA) and -302/-290 (AGGACAGAGCCCA) from exon 1f. Therefore, we hypothesized the possible regulation of CST gene expression by the nuclear receptor PPAR $\alpha$ . To confirm this hypothesis, we first examined whether PPAR $\alpha$  activation influenced murine hepatic CST because the liver is highly sensitive to PPAR $\alpha$ -induced effects. We demonstrated that the amounts of both hepatic CST mRNA and protein, as well as the hepatic contents of sulfatides, were increased with PPAR $\alpha$  activation [8]. However, it is unknown whether PPAR $\alpha$  plays an important role in the transcriptional regulation of CST in other organs, such as kidney, heart, brain, and digestive tract. Specifically, we previously reported that opposing responses concerning CST induction and tissue sulfatide contents between liver and kidney

were found in the kidney dysfunction murine model [4, 5], which suggests organ-specific regulation of sulfatide metabolism. Therefore, extended studies using multiple murine tissues are needed to determine the role of PPAR $\alpha$  in murine CST gene regulation. In the present study, we examined the amounts of sulfatides and CST gene expression in various tissues from wild-type and *Ppara*-null mice that were treated with the PPAR $\alpha$  agonist fenofibrate for the first time.

## Materials and methods

### Mice and treatment

All of the mouse experiments were conducted in accordance with animal study protocols that were approved by the Shinshu University School of Medicine. Wild-type and *Ppara*-null mice were on a SV129 genetic background as previously described [9, 10]. These mice were maintained in a pathogen-free environment under controlled conditions (25 °C; 12-h light/dark cycle) with municipal water and a standard rodent diet *ad libitum*. Twelve-week-old male wild-type and *Ppara*-null mice weighing 25–30 g were used in this study. The mice of each genotype were divided into two groups ( $n=6$ /group). One mouse group was treated with a regular diet that contained 0.1 % (w/w) fenofibrate (Wako Pure Chemical Industries, Osaka, Japan) for 7 days, and the other group continued on a regular diet as a control. Our previous study demonstrated that more than 4 days of PPAR $\alpha$  agonist treatment were required to sufficiently induce most of the PPAR $\alpha$  target genes in mouse liver [11]. Furthermore, our other studies revealed that the induction levels of typical PPAR $\alpha$  target genes by fibrate treatments in kidney and liver were almost identical between the 5 to 7-day treatment group and the 14-day treatment group [12–15]. Therefore, the present study used a 7-day fenofibrate treatment. Seven days after commencing the treatment, the mice were sacrificed under anesthesia for tissue collection. The brain was minced well by scissors prior to freezing on dry ice in order to prepare whole-brain sample. The other tissues were cut into several pieces and then frozen in a similar manner. The tissue samples were stored at -80 °C until analysis.

### Extraction and measurement of sulfatides

The sulfatides were extracted according to the hexane/isopropanol method [16] and were converted to lysosulfatides that consisted of sphingoids, galactoses, and sulfates [17]. The lysosulfatide samples were analyzed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) on a Voyager Elite XL Biospectrometry Workstation (PerSeptive Biosystems, Framingham, MA,

USA) [17]. The sulfatide amounts were calculated as the total amounts of the seven molecular species of lysosulfatides as shown in Table 2.

#### Analysis of mRNA

Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Hilden, Germany), and 2 µg of total RNA were reverse transcribed using oligo dT primers and SuperScript II reverse transcriptase (Invitrogen Corporation, Carlsbad, CA, USA). The generated cDNA was analyzed by quantitative real-time polymerase chain reaction (qPCR) using SYBR Premix Ex Taq II (Takara Bio, Otsu, Japan) on a Thermal Cycler Dice TP800 System (Takara Bio). The gene-specific primers were designed with Primer Express software (Applied Biosystems, Foster City, CA, USA) and ordered from Sigma Aldrich Corporation (St. Louis, MO, USA). The primer pairs are as follows: 5'-ATGGCCTTCACGACCTCAGA-3' and 5'-CGGTCTTGTGCGTCTTCATG-3' for CST (NCBI GenBank accession number, NM\_016922); 5'-ACCACCCCTAACCTGGATCAGT-3' and 5'-ATGGCGTGCACAGAGACACA-3' for ARSA (NM\_009713); 5'-TGGGTCCAGCCTATGGATGT-3' and 5'-GCAGCGTTGGTCTTGGAAAC-3' for ceramide galactosyltransferase (CGT) (NM\_011674); 5'-GAGTGAGAATCATAGCGAGCGATA-3' and 5'-AGTTCCTGGTCCAGCAGCAA-3' for galactosylceramidase (GALC) (NM\_008079); 5'-TGGTATGGTGTCTACTTGAATGAC-3' and 5'-AATTCACCAATCTGGCTGCAC-3' for peroxisomal acyl-CoA oxidase (AOX) (NM\_015729); and 5'-TGCACCACCAACTGCTTAG-3' and 5'-GGATGCAGGGATGATGTTCTG-3' for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (M32599). GAPDH was used as an endogenous control gene. The qPCR analysis was performed by a standard curve method, and the data were expressed as the ratio of target molecule/GAPDH mRNA levels.

#### PPAR $\alpha$ DNA-binding assay

The DNA-binding activity of PPAR $\alpha$  was determined using a PPAR $\alpha$  transcription factor assay kit (Cayman Chemical, Ann Arbor, MI, USA). This assay is based on an enzyme-linked immunosorbent assay using PPRE-immobilized microplates and PPAR $\alpha$ -specific antibodies, which provides similar results to those from a conventionally used radioactive gel shift assay. The DNA-binding assay was performed according to the manufacturer's instructions using whole-tissue lysates (60 µg protein) prepared from fenofibrate-treated and untreated wild-type mice. The sample preparation was performed as described [18–20]. The protein concentrations were measured by a BCA protein assay kit (ThermoFisher Scientific, Waltham, MA, USA). The results were shown as the fold changes relative to those of the wild-type mice without fenofibrate treatment.

#### Statistical analysis

All data were expressed as the mean±standard deviation (SD). The statistical analysis was performed using an unpaired *t*-test (SPSS Statistics 17.0; SPSS Inc., Chicago, IL, USA). A probability value of less than 0.05 was considered statistically significant.

## Results

#### The amounts and compositions of sulfatides

The amounts of sulfatides in six mouse tissues are presented in Table 1. The constitutive amount of sulfatides differed among the organs. A greater amount of sulfatides was detected in the brain and kidney compared with the heart, liver, small intestine and colon in the control mice of both genotypes. There was no difference in the constitutive tissue amounts of sulfatides between the genotypes. The amounts were markedly increased by fenofibrate treatment in the kidney, heart, liver, and small intestine of the wild-type mice, whereas this effect was not observed in the brain or colon of the wild-type mice or in any of the six tissues from the *Ppara*-null mice.

The sphingoid base structures of the tissue sulfatides in the fenofibrate-treated and untreated wild-type mice are presented in Table 2. Although tissue specificity in the sphingoid base structures was found in both groups, fenofibrate-induced compositional changes of these molecular species were not detected. In *Ppara*-null mice, a similar tissue distribution of these sphingoids was also observed with no fenofibrate-induced compositional changes (data not shown).

**Table 1** Sulfatide amounts in various tissues from fenofibrate-treated wild-type and *Ppara*-null mice

	<i>Ppara</i> (+/+)		<i>Ppara</i> (-/-)	
	Control	Fenofibrate	Control	Fenofibrate
Brain	5,138±308	4,960±275	5,550±366	5,330±234
Kidney	1,315±30	1,597±31 *	1,402±46	1,343±41
Heart	17±1	44±2 *	18±1	17±1
Liver	33±2	72±4 *	31±3	32±2
Small intestine	66±5	78±6 *	60±4	61±5
Colon	27±2	28±2	26±2	28±2

Sulfatides were converted to lysosulfatides and were analyzed by MALDI-TOF MS. The amounts of sulfatides (nmol/g tissue) were calculated as the total amounts of the seven molecular species of lysosulfatides as shown in Table 2. The data are expressed as the mean±SD (*n*=6/group). \**P*<0.05, vs. the control of the same genotype

**Table 2** Sphingoid composition of sulfatides in various tissues from fenofibrate-treated wild-type mice

	<i>Ppara</i> (+/+) Control/Fenofibrate						
	d18:2	d18:1	d18:0	t18:0	d20:1	d20:0	t20:0
Brain	3/3	71/70	9/10	3/3	9/10	3/2	2/2
Kidney	7/6	69/72	8/7	7/6	4/3	3/3	2/3
Heart	17/15	36/38	1/1	14/13	13/12	10/11	9/10
Liver	12/11	29/30	11/10	6/6	12/11	10/9	20/23
Small intestine	10/9	16/17	11/10	12/13	11/10	6/5	34/36
Colon	15/14	36/34	9/10	21/23	6/5	10/11	3/3

Sulfatides were converted to lysosulfatides and were analyzed by MALDI-TOF MS. The seven molecular species of lysosulfatides are as follows: sphingadienine (d18:2), (4*E*)-sphingenine (d18:1), sphinganine (d18:0), 4*D*-hydroxysphinganine (t18:0), (4*E*)-icosasphingenine (d20:1), icosasphinganine (d20:0), and 4*D*-hydroxyicosasphinganine (t20:0). The data are expressed as the mean percentages ( $n=6$ /group).

The expression of CST and other enzymes involved in sulfatide metabolism

The mRNA level of CST was increased by fenofibrate treatment in the kidney, heart, liver, and small intestine of the wild-type mice (Fig. 1). However, CST induction by fenofibrate was not found in the brain or colon of the wild-type mice or in any of the tissues of the *Ppara*-null mice. The tissue levels of ARSA mRNA were unchanged by fenofibrate in either genotype (Fig. 2). In any of the wild-type mouse tissues, there was no significant alteration by fenofibrate in the mRNA expression levels of CGT and GALC (data not shown), which are the enzymes that

catalyze the forward and reverse reactions in the synthesis of galactosylceramides from ceramides, respectively. These results suggest that high CST expression was associated with increased sulfatide contents in fenofibrate-treated wild-type mice.


The function of PPAR $\alpha$

As shown in Fig. 3, the DNA-binding activity of PPAR $\alpha$  was increased by fenofibrate treatment in the kidney, heart, liver, and small intestine of wild-type mice, but these increases were absent in the brain and colon. Consistent with this result, the mRNA expression of AOX, the established PPAR $\alpha$  target molecule [21], was also increased by fenofibrate in these four tissues of the wild-type mice only (Fig. 4). Therefore, the enhanced function of PPAR $\alpha$  resulting from fenofibrate treatment occurred in the kidney, heart, liver, and small intestine but not in the brain or colon. These results correlated with the data concerning the levels in sulfatides and CST mRNA.


## Discussion

This study demonstrated that fenofibrate treatment increased the amounts of sulfatides and the expression level of CST mRNA in the kidney, heart, liver, and small intestine in a PPAR $\alpha$ -dependent manner. However, these effects were not found in the brain or colon. Fenofibrate treatment activated PPAR $\alpha$  in the former four tissues but did not affect the brain or colon. Through this evidence, we propose that PPAR $\alpha$  activation induces CST gene expression and enhances sulfatide synthesis in mice.

**Fig. 1** CST mRNA expression levels in various tissues from fenofibrate (FF)-treated wild-type (+/+) and *Ppara*-null (-/-) mice. The mRNA levels were analyzed by qPCR and normalized to GAPDH mRNA. The data are expressed as the mean  $\pm$ SD ( $n=3$ /group). \* $P<0.05$



**Fig. 2** ARSA mRNA expression levels in various tissues from fenofibrate (FF)-treated wild-type (+/+) and *Ppara*-null (-/-) mice. The mRNA levels were analyzed by qPCR and normalized to GAPDH mRNA. The data are expressed as the mean±SD ( $n=3$ /group)




In the current study, there was no significant difference in the constitutive amount of the sulfatides in any of the tissues in the *Ppara*-null mice compared with the wild-type mice. This was also the case with the constitutive mRNA level of sulfatide-metabolizing enzymes including CST. Furthermore, the profile of tissue distribution of sulfatides in this study (Table 1; sulfatide content was higher in the brain and kidney compared with the other organs) was different from the known tissue expression profile of PPAR $\alpha$  (*i.e.*, PPAR $\alpha$  was abundant in the kidney, heart, liver, and small intestine, whereas its expression level was markedly low in the brain and colon) [22, 23]. These findings indicate that PPAR $\alpha$  would not be essential in the regulation of basal tissue sulfatide amounts. It has been reported that the constitutive amounts of distributed tissue sulfatides are mainly regulated by tissue-specific CGT gene expression [24]. In fact, considerable amounts of CGT and its products, galactosylceramides, are known to be markedly detected in sulfatide-rich organs, such as brain and kidney [25]. Therefore, the constitutive tissue sulfatide amounts

would be primarily dependent on tissue CGT expression levels and galactosylceramide content. Because other mechanisms that influence basal tissue sulfatide levels, such as the excretion of sulfatides from each tissue and modulating factors of basal sulfatide metabolism, are unknown, further studies would be required.


In the current study, the large increases in CST mRNA expression and tissue sulfatide levels were detected only in PPAR $\alpha$ -rich organs with PPAR $\alpha$  activation, which suggests that PPAR $\alpha$  plays an important role in enhancing sulfatide synthesis. It has been reported that the effective transcriptional response of PPAR $\alpha$  by its agonist was scarcely detected in low PPAR $\alpha$ -expressing tissues, such as white adipose tissues [26–28], which indicates the significance of tissue levels of PPAR $\alpha$  for its activity. In the current study, the different fenofibrate-induced CST expression levels in each organ might be caused by different tissue-specific PPAR $\alpha$  expression levels. Moreover, the difference in tissue-specific fenofibrate bioavailability might be important. It is known that fenofibrate hardly enters into the central nervous system because of the blood-brain barrier system [29, 30], which might explain the lack of fenofibrate action in the brain. In contrast, it has been reported that fenofibrate is distributed to the colon *via* the blood stream after absorption from the small intestine, and the drug concentration in the colon is almost identical to that in small intestine [31]. Therefore, the poor action of colon PPAR $\alpha$  *via* fenofibrate treatment would be mainly due to low tissue expression levels of PPAR $\alpha$ .

Although this study proposed a mechanism whereby the increased tissue sulfatide level was caused by CST gene induction *via* PPAR $\alpha$  activation, there might be an alternative explanation, *i.e.*, fenofibrate treatment increased the



**Fig. 3** The PPRE-binding activity of PPAR $\alpha$  in various tissues from fenofibrate (FF)-treated wild-type mice. Whole-tissue lysate was used for this assay. The data are expressed as the mean±SD ( $n=3$ /group). The mean value of each control tissue is shown as 1. \* $P<0.05$

**Fig. 4** AOX mRNA expression levels in various tissues from fenofibrate (FF)-treated wild-type (+/+) and *Ppara*-null (-/-) mice. The mRNA levels were analyzed by qPCR and normalized to GAPDH mRNA. The data are expressed as the mean  $\pm$ SD ( $n=3$ /group). \* $P<0.05$



synthetic substrate of sulfatides, galactosylceramides, followed by facilitation of sulfatide synthesis. The tissue amounts of galactosylceramides are primarily regulated by the following 4 enzymes: CST, CGT, ARSA, and GALC. In the present study, transcriptional up-regulation by fenofibrate treatment was observed only in CST, which suggests that the unchanged protein amounts of CGT, ARSA, or GALC scarcely influenced tissue amounts of galactosylceramides. However, we cannot deny the possibility that compensatory modulation of enzymatic activity of sulfatide metabolism *via* fenofibrate treatment, as well as that of galactosylceramide contents, might affect tissue sulfatide levels. Further research to investigate protein amounts and/or enzymatic activity of sulfatide metabolic enzymes and measurement of galactosylceramide content in each organ are needed.

Several previous studies using the C57BL mouse strain have reported that IV<sup>3</sup>-sulfogangliotetraosylceramides were major sulfoglycolipids in the small intestine, whereas I<sup>3</sup>-sulfogalactosylceramides, sulfatides, were scarcely detected [1, 32, 33]. In contrast, our recent study using the SV129 mouse strain revealed a large concentration of sulfatides in the small intestine [34]. With respect to this discrepancy, a previous report has noted the possibility of murine strain-specific differences in the composition and quantity of glycosphingolipids [35]. Furthermore, there might be another methodological difference. The earlier studies that investigated sulfoglycolipids generally used the following method. First, extracted lipids from each organ were separated by thin-layer chromatography, and then, the lipid composition was analyzed by mass spectrometry [36]. This method was useful for identifying novel sulfoglycolipid molecules; however, small sulfoglycolipid concentrations might be difficult to detect. In contrast, our assay system was based on the

analysis of the seven types of lysosulfatides on a MALDI-TOF MS system that was optimized for detecting sulfatides, and the detection sensitivity was greater than that of previous methods [17]. Therefore, the discrepancy in murine small intestine sulfatides might be related to murine genetic background differences and/or the analytical procedures used to detect sulfoglycolipids. Today, it is unclear whether IV<sup>3</sup>-sulfogangliotetraosylceramides are contained in the small intestine of SV129 mice at a significant level. It is known that this molecule is also generated by CST [37]; further research to investigate whether PPAR $\alpha$  regulates the synthesis of other sulfoglycolipids *via* CST as in the case of sulfatides, will be needed.

PPAR $\alpha$  is the central regulator of fatty acid metabolism, particularly for long-chain fatty acids. PPAR $\alpha$  maintains the constitutive expression of genes for several enzymes that are involved in the mitochondrial fatty acid  $\beta$ -oxidation system, such as long-chain acyl-CoA synthetase, and PPAR $\alpha$  activation induces gene expression of these enzymes and stimulates  $\beta$ -oxidation [11, 38–43]. Because the synthesis of sphingolipids is initiated by the transfer of L-serine onto activated long-chain fatty acids, such as palmitoyl-CoA, which arises from the reaction with long-chain acyl-CoA synthetase [44], PPAR $\alpha$  presumably participates in the regulation of overall sphingolipid metabolism. In fact, a previous study has shown ceramide accumulation in human skin cells that are treated with the potent PPAR $\alpha$  agonist Wy-14,643, together with increases in gene expression and activity of serine palmitoyltransferase [45], which is the key enzyme for the initial step in sphingolipid synthesis [46]. Therefore, more studies on sphingolipid metabolism would improve our understanding of the biological function of PPAR $\alpha$ .

Last, the present study provides the possibility of the clinical application of PPAR $\alpha$  agonists to disorders caused by decreased sulfatide levels. Although it remains unclear whether such disorders occur in the kidney, heart, liver, or small intestine, serum sulfatides have been recently recognized as a possible internal inhibitory factor in thrombogenesis [47–49]. Serum sulfatides are produced and secreted mainly by liver as the major component of glycosphingolipids in lipoproteins [50]. In fact, the sphingoid base composition of serum sulfatides is similar to those of liver [34]. Recent clinical studies have revealed a significant reduction in serum sulfatide levels in the final stage of chronic kidney disease, which is strongly correlated with a high incidence of cardiovascular disease at this stage [51–53]. Other studies using a kidney dysfunction mouse model have demonstrated that kidney injuries cause simultaneous reductions in the levels of sulfatides in serum and liver, which is associated with the down-regulation of hepatic CST expression [4, 5]. Furthermore, our recent study demonstrated that hepatic PPAR $\alpha$  activation and resulting hepatic CST induction caused an increase in serum sulfatide concentration [8]. These findings suggest that new PPAR $\alpha$ -activating drugs, which efficiently stimulate hepatic PPAR $\alpha$  while maintaining renal function, might be effective to treat kidney disease patients. Future studies that focus on serum sulfatide function are needed.

**Acknowledgment** This work was supported in part by G.L. Sciences (Tokyo, Japan).

**Conflicts of interest** The authors declare that they have no conflicts of interest.

## References

- Ishizuka, I.: Chemistry and functional distribution of sulfoglycolipids. *Prog. Lipid Res.* **36**, 245–319 (1997)
- Takahashi, T., Suzuki, T.: Role of sulfatide in normal and pathological cells and tissues. *J. Lipid Res.* **53**, 1437–1450 (2012)
- Honke, K., Hirahara, Y., Dupree, J., Suzuki, K., Popko, B., Fukushima, K., Fukushima, J., Nagasawa, T., Yoshida, N., Wada, Y., Taniguchi, N.: Paranodal junction formation and spermatogenesis require sulfoglycolipids. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 4227–4232 (2002)
- Zhang, X., Nakajima, T., Kamijo, Y., Li, G., Hu, R., Kannagi, R., Kyogashima, M., Aoyama, T., Hara, A.: Acute kidney injury induced by protein-overload nephropathy down-regulates gene expression of hepatic cerebroside sulfotransferase in mice, resulting in reduction of liver and serum sulfatides. *Biochem. Biophys. Res. Commun.* **390**, 1382–1388 (2009)
- Sheng, X., Nakajima, T., Wang, L., Zhang, X., Kamijo, Y., Takahashi, K., Tanaka, N., Sugiyama, E., Kyogashima, M., Aoyama, T., Hara, A.: Attenuation of kidney injuries maintains serum sulfatide levels dependent on hepatic synthetic ability: a possible involvement of oxidative stress. *Tohoku J. Exp. Med.* **227**, 1–12 (2012)
- Hirahara, Y., Tsuda, M., Wada, Y., Honke, K.: cDNA cloning, genomic cloning, and tissue-specific regulation of mouse cerebroside sulfotransferase. *Eur. J. Biochem.* **267**, 1909–1916 (2000)
- Podvinec, M., Kaufmann, M.R., Handschin, C., Meyer, U.A.: NUBIScan, an in silico approach for prediction of nuclear receptor response elements. *Mol. Endocrinol.* **16**, 1269–1279 (2002)
- Kimura, T., Nakajima, T., Kamijo, Y., Tanaka, N., Wang, L., Hara, A., Sugiyama, E., Tanaka, E., Gonzalez, F.J., Aoyama, T.: Hepatic cerebroside sulfotransferase is induced by PPAR $\alpha$  activation in mice. *PPAR Res.* **2012**, 174932 (2012)
- Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P.M., Westphal, H., Gonzalez, F.J.: Targeted disruption of the  $\alpha$  isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. *Mol. Cell. Biol.* **15**, 3012–3022 (1995)
- Akiyama, T.E., Nicol, C.J., Fievet, C., Staels, B., Ward, J.M., Auwerx, J., Lee, S.S., Gonzalez, F.J., Peters, J.M.: Peroxisome proliferator-activated receptor- $\alpha$  regulates lipid homeostasis, but is not associated with obesity. *J. Biol. Chem.* **276**, 39088–39093 (2001)
- Aoyama, T., Peters, J.M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., Gonzalez, F.J.: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor  $\alpha$  (PPAR $\alpha$ ). *J. Biol. Chem.* **273**, 5678–5684 (1998)
- Takahashi, K., Kamijo, Y., Hora, K., Hashimoto, K., Higuchi, M., Nakajima, T., Ehara, T., Shigematsu, H., Gonzalez, F.J., Aoyama, T.: Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPAR $\alpha$  deterioration. *Toxicol. Appl. Pharmacol.* **252**, 237–249 (2011)
- Hashimoto, K., Kamijo, Y., Nakajima, T., Harada, M., Higuchi, M., Ehara, T., Shigematsu, H., Aoyama, T.: PPAR $\alpha$  activation protects against anti-Thy1 nephritis by suppressing glomerular NF- $\kappa$ B signaling. *PPAR Res.* **2012**, 976089 (2012)
- Nakajima, T., Tanaka, N., Kanbe, H., Hara, A., Kamijo, Y., Zhang, X., Gonzalez, F.J., Aoyama, T.: Bezafibrate at clinically relevant doses decreases serum/liver triglycerides *via* down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor  $\alpha$ -independent mechanism. *Mol. Pharmacol.* **75**, 782–792 (2009)
- Nakajima, T., Tanaka, N., Li, G., Hu, R., Kamijo, Y., Hara, A., Aoyama, T.: Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice. *Redox Rep.* **15**, 123–130 (2010)
- Hara, A., Radin, N.S.: Lipid extraction of tissues with a low-toxicity solvent. *Anal. Biochem.* **90**, 420–426 (1978)
- Li, G., Hu, R., Kamijo, Y., Nakajima, T., Aoyama, T., Inoue, T., Node, K., Kannagi, R., Kyogashima, M., Hara, A.: Establishment of a quantitative, qualitative, and high-throughput analysis of sulfatides from small amounts of sera by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Anal. Biochem.* **362**, 1–7 (2007)
- Aoyama, T., Yamano, S., Waxman, D.J., Lapenson, D.P., Meyer, U.A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H.V.: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. *J. Biol. Chem.* **264**, 10388–10395 (1989)
- Aoyama, T., Uchida, Y., Kelley, R.I., Marble, M., Hofman, K., Tongsgard, J.H., Rhead, W.J., Hashimoto, T.: A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. *Biochem. Biophys. Res. Commun.* **191**, 1369–1372 (1993)
- Aoyama, T., Ueno, I., Kamijo, T., Hashimoto, T.: Rat very-long-chain acyl-CoA dehydrogenase, a novel mitochondrial acyl-CoA dehydrogenase gene product, is a rate-limiting enzyme in long-chain fatty acid  $\beta$ -oxidation system. cDNA and deduced amino

- acid sequence and distinct specificities of the cDNA-expressed protein. *J. Biol. Chem.* **269**, 19088–19094 (1994)
21. Desvergne, B., Wahli, W.: Peroxisome proliferator-activated receptors: nuclear control of metabolism. *Endocr. Rev.* **20**, 649–688 (1999)
  22. Braissant, O., Fufelle, F., Scotto, C., Dauca, M., Wahli, W.: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- $\alpha$ , - $\beta$ , and - $\gamma$  in the adult rat. *Endocrinology* **137**, 354–366 (1996)
  23. Rakhshandehroo, M., Knoch, B., Müller, M., Kersten, S.: Peroxisome proliferator-activated receptor alpha target genes. *PPAR Res.* **2010**, 612089 (2010)
  24. Honke, K., Zhang, Y., Cheng, X., Kotani, N., Taniguchi, N.: Biological roles of sulfoglycolipids and pathophysiology of their deficiency. *Glycoconj. J.* **21**, 59–62 (2004)
  25. Bosio, A., Binczek, E., Stoffel, W.: Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 13280–13285 (1996)
  26. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., Heyman, R.A., Briggs, M., Deeb, S., Staels, B., Auwerx, J.: PPAR $\alpha$  and PPAR $\gamma$  activators direct a distinct tissue-specific transcriptional response *via* a PPRE in the lipoprotein lipase gene. *EMBO J.* **15**, 5336–5348 (1996)
  27. Martin, G., Schoonjans, K., Lefebvre, A.M., Staels, B., Auwerx, J.: Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR $\alpha$  and PPAR $\gamma$  activators. *J. Biol. Chem.* **272**, 28210–28217 (1997)
  28. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., Latruffe, N.: Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor  $\alpha$  and  $\gamma$  activators in a tissue- and inducer-specific manner. *J. Biol. Chem.* **273**, 16710–16714 (1998)
  29. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., Bems, A.J., Borst, P.: Disruption of the mouse *mdr1a* P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell* **77**, 491–502 (1994)
  30. Berger, J., Albet, S., Bentejac, M., Netik, A., Holzinger, A., Roscher, A.A., Bugaut, M., Forss-Petter, S.: The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. *Eur. J. Biochem.* **265**, 719–727 (1999)
  31. Mogi, M., Abe, S., Hayashi, T., Tsutsumi, S.: Studies on the metabolic fate of fenofibrate (1). Absorption, distribution and excretion after the single and repeated administration to rats. *Jpn. Pharmacol. Ther.* **23**, S1117–S1133 (1995)
  32. Breimer, M.E., Hansson, G.C., Karlsson, K.A., Leffler, H.: The preparative separation of sialic acid-containing lipids from sulphate group-containing glycolipids from small intestine of different animals. Analysis by thin-layer chromatography and detection of novel species. *J. Biochem.* **93**, 1473–1485 (1983)
  33. Leffler, H., Hansson, G.C., Strömberg, N.: A novel sulfoglycosphingolipid of mouse small intestine, IV<sup>3</sup>-sulfogangliotetraosylceramide, demonstrated by negative ion fast atom bombardment mass spectrometry. *J. Biol. Chem.* **261**, 1440–1444 (1986)
  34. Li, G., Hu, R., Kamijo, Y., Nakajima, T., Aoyama, T., Ehara, T., Shigematsu, H., Kannagi, R., Kyogashima, M., Hara, A.: Kidney dysfunction induced by protein overload nephropathy reduces serum sulfatide levels in mice. *Nephrology* **14**, 658–662 (2009)
  35. Coles, L., Hay, J.B., Gray, G.M.: Factors affecting the glycosphingolipid composition of murine tissues. *J. Lipid Res.* **11**, 158–163 (1970)
  36. Farwanah, H., Kolter, T.: Lipidomics of glycosphingolipids. *Metabolites* **2**, 134–164 (2012)
  37. Honke, K., Yamane, M., Ishii, A., Kobayashi, T., Makita, A.: Purification and characterization of 3'-phosphoadenosine-5'-phosphosulfate:GalCer sulfotransferase from human renal cancer cells. *J. Biochem.* **119**, 421–427 (1996)
  38. Watanabe, K., Fujii, H., Takahashi, T., Kodama, M., Aizawa, Y., Ohta, Y., Ono, T., Hasegawa, G., Naito, M., Nakajima, T., Kamijo, Y., Gonzalez, F.J., Aoyama, T.: Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor  $\alpha$  associated with age-dependent cardiac toxicity. *J. Biol. Chem.* **275**, 22293–22299 (2000)
  39. Kamijo, Y., Hora, K., Tanaka, N., Usuda, N., Kiyosawa, K., Nakajima, T., Gonzalez, F.J., Aoyama, T.: Identification of functions of peroxisome proliferator-activated receptor  $\alpha$  in proximal tubules. *J. Am. Soc. Nephrol.* **13**, 1691–1702 (2002)
  40. Nakajima, T., Kamijo, Y., Tanaka, N., Sugiyama, E., Tanaka, E., Kiyosawa, K., Fukushima, Y., Peters, J.M., Gonzalez, F.J., Aoyama, T.: Peroxisome proliferator-activated receptor  $\alpha$  protects against alcohol-induced liver damage. *Hepatology* **40**, 972–980 (2004)
  41. Kamijo, Y., Hora, K., Nakajima, T., Kono, K., Takahashi, K., Ito, Y., Higuchi, M., Kiyosawa, K., Shigematsu, H., Gonzalez, F.J., Aoyama, T.: Peroxisome proliferator-activated receptor  $\alpha$  protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. *J. Am. Soc. Nephrol.* **18**, 176–188 (2007)
  42. Kamijo, Y., Hora, K., Kono, K., Takahashi, K., Higuchi, M., Ehara, T., Kiyosawa, K., Shigematsu, H., Gonzalez, F.J., Aoyama, T.: PPAR $\alpha$  protects proximal tubular cells from acute fatty acid toxicity. *J. Am. Soc. Nephrol.* **18**, 3089–3100 (2007)
  43. Tanaka, N., Moriya, K., Kiyosawa, K., Koike, K., Gonzalez, F.J., Aoyama, T.: PPAR $\alpha$  activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. *J. Clin. Invest.* **118**, 683–694 (2008)
  44. Bikman, B.T., Summers, S.A.: Ceramides as modulators of cellular and whole-body metabolism. *J. Clin. Invest.* **121**, 4222–4230 (2011)
  45. Rivier, M., Castiel, I., Safonova, I., Ailhaud, G., Michel, S.: Peroxisome proliferator-activated receptor- $\alpha$  enhances lipid metabolism in a skin equivalent model. *J. Invest. Dermatol.* **114**, 681–687 (2000)
  46. Hanada, K.: Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. *Biochim. Biophys. Acta* **1632**, 16–30 (2003)
  47. Hara, A., Kutsukake, Y., Uemura, K.I., Taketomi, T.: Anticoagulant activity of sulfatide and its anti-thrombotic effect in rabbit. *J. Biochem.* **113**, 781–785 (1993)
  48. Hara, A., Uemura, K., Taketomi, T.: Sulfatide prolongs blood-coagulation time and bleeding time by forming a complex with fibrinogen. *Glycoconj. J.* **13**, 187–194 (1996)
  49. Kyogashima, M., Sakai, T., Onaya, J., Hara, A.: Roles of galactose and sulfate residues in sulfatides for their antagonistic functions in the blood coagulation system. *Glycoconj. J.* **18**, 245–251 (2001)
  50. Hara, A., Taketomi, T.: Occurrence of sulfatide as a major glycosphingolipid in WHHL rabbit serum lipoproteins. *J. Biochem.* **102**, 83–92 (1987)
  51. Hu, R., Li, G., Kamijo, Y., Aoyama, T., Nakajima, T., Inoue, T., Node, K., Kannagi, R., Kyogashima, M., Hara, A.: Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure. *Glycoconj. J.* **24**, 565–571 (2007)
  52. Wang, L., Kamijo, Y., Matsumoto, A., Nakajima, T., Higuchi, M., Kannagi, R., Kyogashima, M., Aoyama, T., Hara, A.: Kidney transplantation recovers the reduction level of serum sulfatide in ESRD patients *via* processes correlated to oxidative stress and platelet count. *Glycoconj. J.* **28**, 125–135 (2011)
  53. Kamijo, Y., Wang, L., Matsumoto, A., Nakajima, T., Hashimoto, K., Higuchi, M., Kyogashima, M., Aoyama, T., Hara, A.: Long-term improvement of oxidative stress *via* kidney transplantation ameliorates serum sulfatide levels. *Clin. Exp. Nephrol.* (in press)